Latest News
- ARCHIVIERT
Monday - December 21, 2015
Bayer and CRISPR Therapeutics AG join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases
The novel joint venture focuses on fundamental breakthrough treatments through first systemic application of promising CRISPR-Cas9 gene editing technology / Bayer is investing USD 335 million in a long-term alliance with CRISPR Therapeutics through new Bayer LifeScience Center unit / The joint venture will combine two leading knowledge areas: CRISPR-Cas9 from CRISPR Therapeutics as well as protein engineering and disease know-how by Bayer » more
- ARCHIVIERT
Friday - December 18, 2015
Not intended for U.S. and UK Media
Bayer Receives Positive CHMP Opinion for BAY 81-8973 for the Treatment of Hemophilia A in Patients in EU » more
- ARCHIVIERT
Wednesday - December 9, 2015
Not intended for U.S. and UK Media
Article in German newspaper Handelsblatt regarding Xarelto » more
- ARCHIVIERT
Tuesday - December 8, 2015
Not intended for U.S. and UK Media - 2015 American Society of Hematology (ASH) Annual Meeting:
New Real World Data of Bayer’s Xarelto® in Deep Vein Thrombosis Treatment Confirm Low Rates of Major Bleeding Seen in Pivotal Trial
XALIA is the first published prospective real world study to confirm the benefit of a NOAC in the treatment of patients with deep vein thrombosis (DVT) in routine clinical practice / Real world evidence from CALLISTO Research Programme shows low rates of major bleeding with Xarelto in the treatment of patients with cancer-associated thrombosis / Real world insights expand on pivotal Clinical Trial Programme confirming the safety and effectiveness of Xarelto in a broad range of patients » more
- ARCHIVIERT
Friday - November 20, 2015
Not intended for U.S. and UK Media
Bayer’s new five-year-contraceptive submitted for EU and US Marketing Authorization
Clinical studies demonstrated efficacy of new long-acting contraceptive with lowest available daily hormone dose for five years of contraception » more
- ARCHIVIERT
Friday - October 30, 2015
Not intended for U.S. and UK Media
Bayer Receives EU Approval for EYLEA® for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization » more
- ARCHIVIERT
Friday - September 25, 2015
Not intended for U.S. and UK Media - Aflibercept solution for injection into the eye:
Bayer’s Eye Drug Recommended for EU Approval in Fifth Indication » more
- ARCHIVIERT
Thursday - September 24, 2015
Not intended for U.S. and UK Media
Bayer’s Xarelto® Approved in Japan for the Treatment and Secondary Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis » more
- ARCHIVIERT
Friday - September 18, 2015
Not intended for U.S. and UK Media - EYLEA® (aflibercept solution for injection into the eye):
Three-Year Results with EYLEA Show Sustained Improvement in Vision for People with Diabetic Macular Edema » more
- ARCHIVIERT
Tuesday - September 1, 2015
Not intended for U.S. and UK Media - Late-Breaking Science at ESC Congress 2015:
New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer’s Xarelto® in Patients with Non-Valvular Atrial Fibrillation
Insights from more than 45,000 real-world patients with atrial fibrillation (AF) confirm low bleeding rates for Xarelto / Late-breaking XANTUS study expands on ROCKET AF data, demonstrating Xarelto provides highly effective stroke prevention in both high- and lower-risk patients / Two-year findings from an ongoing post-marketing safety surveillance (PMSS) study show rates and patterns of major bleeding to be consistent with ROCKET AF » more
- ARCHIVIERT
Monday - August 31, 2015
Not intended for U.S. and UK Media
Bayer Expands Finerenone Clinical Development Programme with Three Phase III Studies in Patients with Chronic Heart Failure and Patients with Diabetic Kidney Disease
Decision based on data of four dose-finding studies in patients with chronic heart failure and diabetic kidney disease » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Thursday, February 25, 2021
Financial News Conference on the Full Year 2020 Results
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV